FAME 1 Eye research study - A new treatment for retinopathy in type 1 diabetes

Type 1 diabetes with eye changes (retinopathy)

Fenofibrate has proved to slow the development of diabetic retinopathy and need for laser surgery for people with type 2 diabetes. The purpose of this study is to test whether Fenofibrate is also safe and effective in reducing retinopathy for people with type 1 diabetes.

Category
Trial Status
Recruiting
Trial Phase
Phase 3 Drug Trial
Trial contact details
Contact Person
Yvonne Gautam
What you need to know

Who can take part?

  • People with type 1 diabetes.
  • Those aged 18 years or over
  • People with at least one eye with mild non-proliferative diabetic eye disease (retinopathy)

What is involved for you?

  • vital signs taken (blood pressure, heart rate), height, weight
  • electro cardiograms (ECGs)
  • simple tests of foot sensation
  • eye tests and photos taken
  • blood and urine samples
  • questionnaires

Trial dates

This trial is accepting participants until June 2024.

All research clinical trials news

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.

23

May

Mater launches trial of Australian-first flu vaccine

Displaying results 1-3 (of 18)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|